Autolus Therapeutics plc (6A3A) - Total Liabilities

Latest as of June 2026: €418.39 Million EUR ≈ $489.14 Million USD

Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has total liabilities worth €418.39 Million EUR (≈ $489.14 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Autolus Therapeutics plc (6A3A) asset resilience to evaluate the company's liquid asset resilience ratio.

Autolus Therapeutics plc - Total Liabilities Trend (2017–2025)

This chart illustrates how Autolus Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Autolus Therapeutics plc's balance sheet.

Autolus Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Autolus Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
Beijing Huaru Technology Co. Ltd. SHE:301302	China	CN¥288.81 Million
First Trust High Yield Opportunities 2027 Term Fund NYSE:FTHY	USA	$192.09 Million
The York Water Company NASDAQ:YORW	USA	$447.52 Million
Helen of Troy Limited F:HT2	Germany	€1.32 Billion
Anhui Transport Consulting & SHG:603357	China	CN¥2.93 Billion
Jereissati Participações S.A. SA:IGTI3	Brazil	R$5.13 Billion
Vastned Retail Belgium BR:VASTB	Belgium	€562.58 Million
Radium Development Berhad KLSE:5313	Malaysia	RM728.92 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Autolus Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Autolus Therapeutics plc (6A3A) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.89	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	5.59	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.85	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Autolus Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Autolus Therapeutics plc (2017–2025)

The table below shows the annual total liabilities of Autolus Therapeutics plc from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	€410.94 Million ≈ $480.43 Million	+15.63%
2024-12-31	€355.40 Million ≈ $415.50 Million	+34.67%
2023-12-31	€263.91 Million ≈ $308.54 Million	+37.74%
2022-12-31	€191.60 Million ≈ $224.00 Million	+107.72%
2021-12-31	€92.24 Million ≈ $107.84 Million	+9.54%
2020-12-31	€84.20 Million ≈ $98.44 Million	+72.93%
2019-12-31	€48.69 Million ≈ $56.93 Million	+174.49%
2018-12-31	€17.74 Million ≈ $20.74 Million	+192.69%
2017-12-31	€6.06 Million ≈ $7.09 Million	--

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$522.77 Million

€447.15 Million EUR

Market Cap Rank

#12583 Global

#1343 in Germany

Share Price

€1.68

Change (1 day)

+3.07%

52-Week Range

€1.06 - €2.16

All Time High

€40.10